Abstract

IN-VITRO ACTIVITY OF TIGECYCLINE AGAINST CLINICAL ISOLATES OF ACINETOBACTER BAUMANNII BY E-TEST METHOD IN RABAT

*Es-said Imane, Benouda Amina 

ABSTRACT

Introduction: The progressively increasing resistance of A. baumannii to widely used antibiotics such as broad spectrum cephalosporins, carbapenems, fluoroquinolones and aminoglycosides is a major problem, urgently requiring more antibiotic options. Tigecycline has been used mainly as part of a combination regimen for the treatment of some infections and most patients included in these reports had good clinical outcomes. Our study aimed to determine the in-vitro activity of this antibiotic against clinical A. baumannii isolates. Materials and methods: The study was conducted in the university hospital Sheikh Zaid in Rabat. The study included fifty strains of Acinetobacter baumannii isolated from fifty different patients in different units (ICUs, medicine and surgery) Susceptibility testing of these antibiotics was performed according to the method of distributable disks on Mueller Hinton.The interpretation of the minimum inhibitory concentration (MIC) of tigecycline against isolates of A. baumannii was given according to Administration U.S. Food and Drug Administration (FDA). Results: A substantial number of the isolates were found to be resistant to imipenem (80%), ciprofloxacin (88%), amikacin (80%), gentamicin (88%), amoxicillin-clavulanic acid (98%), sulfamethoxazole-trimethoprim (84%) and for all these six antibiotics (70%). Susceptibility to tigecycline varied from 25.71% (susceptible isolates) to 74.29% (intermediate isolates) for 0% (resistant isolates). Conclusion: These in vitro results show that tigecycline has good bacteriostatic activity against A. baumannii, including strains multiresistants.

Keywords: Tigecycline, Multidrug resistant, Acinetobacter baumannii.